Bentong Yu
Overview
Explore the profile of Bentong Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu C, Liu M, Li Y, Peng X, Zhou W, Zhang W, et al.
Discov Oncol
. 2025 Mar;
16(1):270.
PMID: 40050481
Background: Chromatin modified protein 4C (CHMP4C) is a charged polyvesicular protein (CHMP) that is involved in the composition of the endosomal sorting complex (ESCRT-III) required for transport III and promotes...
2.
Chen T, Wen J, Shen X, Shen J, Deng J, Zhao M, et al.
NPJ Digit Med
. 2025 Jan;
8(1):69.
PMID: 39875799
Existing prognostic models are useful for estimating the prognosis of lung adenocarcinoma patients, but there remains room for improvement. In the current study, we developed a deep learning model based...
3.
Zhao M, Xue G, He B, Deng J, Wang T, Zhong Y, et al.
Nat Commun
. 2025 Jan;
16(1):84.
PMID: 39747216
Diagnosing lung cancer from indeterminate pulmonary nodules (IPLs) remains challenging. In this multi-institutional study involving 2032 participants with IPLs, we integrate the clinical, radiomic with circulating cell-free DNA fragmentomic features...
4.
Zou G, Jiang L, Xu B, Xu J, Zeng Z, Xia L, et al.
J Thorac Dis
. 2024 Dec;
16(11):7941-7957.
PMID: 39678848
The scarcity of viable donor lungs is a formidable obstacle in lung transplantation (LTx) surgery. This issue significantly hinders the availability of this life-saving procedure for patients in need. To...
5.
Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al.
Lancet Respir Med
. 2024 Nov;
13(2):119-129.
PMID: 39581197
Background: Treatment guidelines recommend neoadjuvant or adjuvant chemotherapy, with or without immune checkpoint inhibitors, for resectable non-small-cell lung cancer (NSCLC). We report the interim results for the phase 3 RATIONALE-315...
6.
He Y, Gan M, Wang Y, Huang T, Wang J, Han T, et al.
Cell Death Dis
. 2024 Nov;
15(11):789.
PMID: 39496588
No abstract available.
7.
Liu R, Zhou D, Yu B, Zhou Z
Cell Signal
. 2024 May;
120:111226.
PMID: 38740232
Lung adenocarcinoma (LUAD), responsible for nearly half of lung cancer cases, is one of the most prevalent and lethal malignant tumors globally. There is increasing evidence suggesting that the oncoprotein...
8.
Xi Y, Xi L, Tan J, Yu C, Shen W, Yu B
Environ Toxicol
. 2024 Apr;
PMID: 38619376
This study offers a detailed exploration of lung adenocarcinoma (LUAD), addressing its heterogeneity and treatment challenges through a multi-faceted analysis that includes gene expression, genetic subtyping, pathway analysis, immune assessment,...
9.
Yin H, Wang L, Li F, Wang D, Zhang Z, Yu B, et al.
Transl Cancer Res
. 2023 Dec;
12(11):3222.
PMID: 38130303
[This retracts the article DOI: 10.21037/tcr.2020.04.26.].
10.
Yu B, Liu M, Jiang L, Xu C, Hu H, Huang T, et al.
Adv Healthc Mater
. 2023 Dec;
13(11):e2303643.
PMID: 38115727
Photodynamic therapy (PDT) with aggregation-induced emission (AIE) photosensitizers (PSs) is a promising therapeutic strategy to achieve better anticancer results. However, eradicating solid tumors completely by PDT alone can be difficult...